Business Information
The group's principal activities are research, development, manufacture and commercialization of nasally administered prescription pharmaceuticals. They are into developing molecular biology-based technologies for delivering both small and large molecule drugs. The group has commercial interest in two nasal drug products, stadol(R) ns(TM) (butorphanol tartrate) and nascobal(R) (cyanocobalamin, usp). Stadol(R) ns(TM) (butorphanol tartrate) is a nasally administered opioid pain relief medication for the treatment of acute pain. Nascobal(R) (cyanocobalamin, usp) is a nasal vitamin b-12 product that provides patient benefits over the injectable therapy for chronic b-12 deficiency anaemia. At 31-Dec-2003, the group has 195 patents.
|
|
Name |
Title
|
Email
|
| Steven Quay | Chmn., CEO, Pres. | N/A | | Paul Johnson | Sr. VP - Research, Development, Chief Scientific Officer | N/A | | David Wormuth | Sr. VP - Operations | N/A | | Gordon Brandt | Exec. VP - Clinical Research, Medical Affairs | N/A | | Timothy Duffy | Exec. VP - Marketing, Business Development | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 28,490 | (26,877) | | 2005 | 7,449 | (32,163) | | 2004 | 1,847 | (28,609)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
